Direct evidence of CRISPR-Cas9-mediated mitochondrial genome editing
Rui Bi, Yu Li, Min Xu, Quanzhen Zheng, Dengfeng Zhang, Xiao Li, Guolan Ma, Bo-Lin Xiang, Xiaojia Zhu, Hui Zhao, Xingxu Huang, Ping Zheng, Yong‐Gang Yao
Abstract
gene, respectively. We confirmed that the mito-Cas9 system was transported into mitochondria and enabled knockin of exogenous single-stranded DNA oligonucleotides (ssODNs) into mtDNA based on proteinase and DNase protection assays. Successful knockin of exogenous ssODNs into mtDNA was further validated using polymerase chain reaction-free third-generation sequencing technology. We also demonstrated that RS-1, an agonist of RAD51, significantly increased knockin efficiency of the mito-Cas9 system. Collectively, we provide direct evidence that mtDNA can be edited using the CRISPR-Cas9 system. The mito-Cas9 system could be optimized as a promising approach for the treatment of mitochondrial diseases caused by pathogenic mtDNA mutations, especially those with homoplasmic mtDNA mutations.